右佐匹克隆合并艾司西肽普兰治疗广泛性焦虑伴失眠的对照研究

中国临床药理学与治疗学 ›› 2014, Vol. 19 ›› Issue (1): 54-57.

右佐匹克隆合并艾司西肽普兰治疗广泛性焦虑伴失眠的对照研究

李亚玲, 叶建飞, 李婷, 李国荣

嘉兴市康慈医院,嘉兴 314500,浙江

收稿日期:2013-03-16 修回日期:2013-11-12 出版日期:2014-01-27 发布日期:2014-02-12
通讯作者: 李国荣,男,主要从事心身医学的临床诊治及发病机制的研究。E-mail: liguorong1805@sina.com
作者简介:李亚玲,女,在读硕士,主要从事心身医学的临床诊治及发病机制的研究。Tel: 13758339880 E-mail: liyaling197898@163.corn

The control research of escitalopram with or without eszopiclone on the treatment of generalized anxiety disorder with insomnia

LI Ya-ling, YE Jian-fei, LI Ting , LI Guo-rong

Kangci Hospital of Jiaxing, Jiaxing 314500, Zhejiang,China

Received:2013-03-16 Revised:2013-11-12 Online:2014-01-27 Published:2014-02-12

摘要/Abstract

摘要： 目的: 比较广泛性焦虑伴失眠患者在抗焦虑治疗(艾司西酞普兰)初期合用或不用右佐匹克隆对患者失眠、焦虑症状的疗效与安全性。方法: 将100例符合“中国精神障碍分类与诊断标准(第三版)”(CCMD-3)广泛性焦虑伴有失眠的患者随机分为试验组(52例)和对照组(48例)。试验组给予艾司西酞普兰合并右佐匹克隆治疗,对照组单用艾司西酞普兰治疗,观察期为8周。用汉密尔顿焦虑量表(HAMA)评定患者焦虑症状及疗效,用睡眠障碍量表(SDRS)评定失眠症状和疗效,同时用不良反应量表(TESS)和实验室检查评估治疗安全性。结果: 试验组在治疗第1周末HAMA评分明显下降(P＜0.01),对照组在第2周末HAMA评分明显下降(P＜0.01),试验组在治疗后第1、2、4、6周末HAMA总分均低于对照组(P<0.05),第8周末差异无统计学意义(P> 0.05)。2组在治疗后第1、2、4周末SDRS总分均低于治疗前(P＜0.01)。试验组在第1、2、4周末SDRS总分均低于对照组(P＜0.01)。试验组较对照组更易发生头痛、口苦、口干、恶心及困倦感(P＜0.05)。结论: 艾司西酞普兰合并右佐匹克隆治疗广泛性焦虑伴失眠,有助于快速改善患者的失眠和焦虑症状,但副反应相对明显。

关键词: 广泛性焦虑障碍, 失眠, 右佐匹克隆, 艾司西酞普兰

Abstract: AIM: To observe the efficacy and safety of escitalopram with or without eszopiclone on the treatment of generalized anxiety disorder with insomnia patients.METHODS: 100 patients who met the CCMD-3 criteria for generalized anxiety disorder with insomnia were randomly divided into the experimental group (n=52) and the control group (n=48). The experimental group were treated with escitalopram combining with eszopiclone, and the control group with escitalopram monotherapy. The trial lasted 8 weeks. The anxiety status and efficacy was evaluated with HAMA at the baseline,1st, 2nd, 4th, 6th and 8th weekend respectively, the insomnia status with SDRS, and the safety with TESS and laboratory examination.RESULTS: The HAMA scores of the experimental group and the control group declined significantly by the end of 1st week (P＜0.01)and the end of 2nd week (P＜0.01)respectively, and the reduction of HAMA scores of the experimental group was more significant than the control group at the end of 1st, 2nd, 4th and 6th weekend (P＜0.05), while there was no significant difference between the two groups at the end of 8th weekend (P>0.05). The SDRS scores of the experimental group declined significantly by the end of 1st week (P＜0.01), and the reduction of SDRS scores of the experimental group was more significant than the control group at the end of 1st, 2nd, and 4th weekend (P＜0.01). Side events happened more easily in the experimental group than in the control group such as headache, mouth pain, dry mouth, nausea and drowsiness(P＜0.05) .CONCLUSION: Escitalopram with eszopiclone on the treatment of generalized anxiety disorder with insomnia patients contribute to a rapid improvement in insomnia and anxiety, but the side effects are relatively obvious.

Key words: Generalized anxiety disorder, Insomnia, Escitalopram, Eszopiclone

中图分类号:

R749

李亚玲, 叶建飞, 李婷, 李国荣. 右佐匹克隆合并艾司西肽普兰治疗广泛性焦虑伴失眠的对照研究[J]. 中国临床药理学与治疗学, 2014, 19(1): 54-57.

LI Ya-ling, YE Jian-fei, LI Ting , LI Guo-rong. The control research of escitalopram with or without eszopiclone on the treatment of generalized anxiety disorder with insomnia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(1): 54-57.

参考文献

[1] Johnson EO,Roth T, Breslau N.The association of insomnia with anxiety disorders and depression:exploration of the direction of risk[J].J Psychiatry Res,2006,40(8):700-708.
[2] 陆峥,陈发展.焦虑性失眠的药物治疗[J].世界临床药物,2011,32(4):205-208.
[3] Pollack M,Kinrys G,Krystal A.Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder[J].Arch Gen Psychiatry,2008,65(5):551-562.
[4] Shi YY,He L.SHEsis,a powerful software platform for analyses of linkage disequilibrium, haplotype construction,and genetic association at polymorphism loci[J].Cell Res, 2005,15:97-98.
[5] 肖卫东,刘平,马弘,等.睡眠障碍评定量表的信度和效度分析[J].中国心理卫生杂志,2007,21(1):40,41,51.
[6] 张明园.精神科评定量表手册[M].长沙:湖南科学技术出版社,2003: 133-136.
[7] Davidson JR,Zhang W,Connor KM,et al.A psychopharmacological treatment algorithm for generalized anxiety disorder(GAD)[J]. J Psychopharmacol, 2008,10(2):1-24.
[8] 季建林.抑郁与焦虑所致的失眠[J].中国全科医师杂志,2008,12(7):746-750.
[9] 何梅,周朝当.焦虑症患者睡眠状况与焦虑症状相关性研究[J].临床心身疾病杂志,2012,18(2):160-161.
[10] Monti JM,Monti D.Sleep disturbance in generalized anxiety disorder and its treatment[J].Sleep Med Rev,2000,4(3):263-276.
[11] 张卫华,王雪芹,付艺,等.右旋佐匹克隆治疗失眠症的随机双盲对照研究[J].中国心理卫生杂志,2009,23(8):579-58.
[12] 沈仲夏,关铁峰,沈鑫华. 艾司西酞普兰与文拉法辛缓释剂治疗广泛性焦虑障碍的对照研究[J]. 中国临床药理学与治疗学,2012,17(10):1167-1171.
[13] 王祖祈.抗抑郁药[M] //沈渔邨,主编.精神病学.5版.北京:人民卫生出版社,2011: 898.
[14] 阮晶,姚晨,张素敏,等.右旋与消旋佐匹克隆治疗睡眠障碍的随机双盲双模拟临床试验[J]. 中国临床药理学杂志,2006,22(1):19-21.
[15] 张鸿燕,原岩波,黄兰,等.右旋佐匹克隆I期耐受性试验[J].中国临床药理学杂志,2002,20(4):258-260.
[16] 司天梅,李森强,舒良. 艾司佐匹克隆的临床研究进展及应用[J]. 中国新药杂志,2006,l5(2):145-148.